Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed.

1. Protocol for in vitro profiling of key TNF downstream signaling pathways involved in cell death and pro-survival signaling in cancer cells.STAR protocols · 2026
   Article
2. Antigen-directed single domain antibody-based TNFR1 agonists elicit preferential killing of HER2-overexpressing cancer cells.iScience · 2026
   Article
3. Isolated Limb Perfusion for Extremity Soft Tissue Sarcoma and Malignant Melanoma.Indian journal of surgical oncology · 2024
   Review
4. Interleukin-38 promotes tumor growth through regulation of CD8Cancer immunology, immunotherapy : CII · 2021
   Article
5. Targeted Antitumor Mechanism of C-PC/CMC-CD55sp Nanospheres in HeLa Cervical Cancer Cells.Frontiers in pharmacology · 2020
   Article
6. CEST MRI monitoring of tumor response to vascular disrupting therapy using high molecular weight dextrans.Magnetic resonance in medicine · 2019
   Article
7. Alk5 inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors.JCI insight · 2016
   Article
8. Sundew plant, a potential source of anti-inflammatory agents, selectively induces G2/M arrest and apoptosis in MCF-7 cells through upregulation of p53 and Bax/Bcl-2 ratio.Cell death discovery · 2016
   Article
9. TNF-α promoter polymorphisms and risk of recurrence in patients with squamous cell carcinomas of the nonoropharynx.International journal of cancer · 2014
   Article
10. Genetic variants in TNF-α promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy.International journal of cancer · 2014
    Article
11. Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.Antioxidants & redox signaling · 2014
    Review
12. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.Advanced drug delivery reviews · 2012
    Review
13. Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses.PloS one · 2012
    Article
14. Squamous carcinoma cells influence monocyte phenotype and suppress lipopolysaccharide-induced TNF-alpha in monocytes.Inflammation · 2010
    Article
15. Vascular regeneration by local growth factor release is self-limited by microvascular clearance.Circulation · 2009
    Article
16. Gene expression polymorphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor necrosis factors-alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma.Journal of cancer research and clinical oncology · 2008
    Article
17. The role of tumor necrosis factor-alpha in systemic lupus erythematosus.Arthritis research & therapy · 2008
    Review
18. Tumor immunoediting and immunosculpting pathways to cancer progression.Seminars in cancer biology · 2007
    Review
19. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.Neoplasia (New York, N.Y.) · 2006
    Article
20. Type I interferon and TNFalpha cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells.Oncogene · 2004
    Article

Corrections and comments

• Comment on
  Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.2002

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as